In a trial with more than 1,000 participants between the ages of 65 and 85, the drug “did not clear plaque or halt accumulation of amyloid,” the protein associated with the disease, Eli Lilly said in a news release.
“While this study was negative, the unique data generated have increased our understanding of preclinical Alzheimer’s disease and will advance the next generation of Alzheimer’s disease prevention studies,” John Sims, head of medical and global brand development for the drug, said in a news release.
Eli Lilly is developing two other Alzheimer’s treatment candidates — donanemab and remternetug — which are in late-stage clinical trials. The investigational antibodies “are different from solanezumab in that they specifically target deposited amyloid plaque and have been shown to lead to plaque clearance in treated patients,” the drugmaker said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
